PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Edson College, Arizona State University, Phoenix, AZ, USA. Electronic address: john.rizk@lau.edu.\', \'Division of Infectious Diseases, Department of Medicine, University of California, Irvine, School of Medicine, Irvine, CA, USA; Department of Molecular Biology and Biochemistry, University of California, Irvine, School of Medicine, Irvine, CA, USA.\', \'Division of Nephrology, Hypertension and Kidney Transplantation, University of California, Irvine, School of Medicine, Irvine, CA, USA; Department of Epidemiology, University of California, Los Angeles, UCLA Fielding School of Public Health, Los Angeles, CA, USA.\', \'Brigham and Women\'s Hospital and Harvard Medical School, Boston, MA, USA.\', \'John Ochsner Heart and Vascular Institute, Ochsner Clinical School - the University of Queensland School of Medicine, New Orleans, LA, USA.\', \'Department of Family Medicine, American University of Beirut Medical Center, Beirut, Lebanon.\', \'Edson College, Arizona State University, Phoenix, AZ, USA.\', \'National Coalition on Health Care, Washington, DC, USA.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S1359-6446(20)30509-210.1016/j.drudis.2020.11.025
?:hasPublicationType
?:journal
  • Drug discovery today
is ?:pmid of
?:pmid
?:pmid
  • 33253920
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 2.008
?:rankingScore_hIndex
  • 150
is ?:relation_isRelatedTo_publication of
?:title
  • Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all